Hangzhou Minsheng Healthcare Co Ltd
Hangzhou Minsheng Healthcare Co., Ltd. engages in the research, development, production, and sale of vitamins and mineral supplements, OTC drugs, and health foods in China. The company offers healthy products, such as fish and algae oil gel candy, collagen peptide vitamin D calcium chewable tablets, blueberry lutein ester candy tablets, and probiotic solid beverage. It also provides multivitamin,… Read more
Hangzhou Minsheng Healthcare Co Ltd (301507) - Net Assets
Latest net assets as of June 2025: CN¥1.68 Billion CNY
Based on the latest financial reports, Hangzhou Minsheng Healthcare Co Ltd (301507) has net assets worth CN¥1.68 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.97 Billion) and total liabilities (CN¥289.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.68 Billion |
| % of Total Assets | 85.32% |
| Annual Growth Rate | 43.76% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 65.36 |
Hangzhou Minsheng Healthcare Co Ltd - Net Assets Trend (2021–2024)
This chart illustrates how Hangzhou Minsheng Healthcare Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hangzhou Minsheng Healthcare Co Ltd (2021–2024)
The table below shows the annual net assets of Hangzhou Minsheng Healthcare Co Ltd from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.53 Billion | +3.92% |
| 2023-12-31 | CN¥1.47 Billion | +147.94% |
| 2022-12-31 | CN¥594.13 Million | +15.34% |
| 2021-12-31 | CN¥515.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hangzhou Minsheng Healthcare Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 19345929040.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥191.30 Million | 12.50% |
| Other Components | CN¥1.34 Billion | 87.50% |
| Total Equity | CN¥1.53 Billion | 100.00% |
Hangzhou Minsheng Healthcare Co Ltd Competitors by Market Cap
The table below lists competitors of Hangzhou Minsheng Healthcare Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ascopiave S.p.A
PINK:ASCOF
|
$220.54 Million |
|
AB Fagerhult
F:2F0
|
$220.55 Million |
|
CLOUDBERRY CL.EN. NK -25
F:52K
|
$220.61 Million |
|
Porvair plc
PINK:PVARF
|
$220.64 Million |
|
KARAT PACKAGING DL -001
F:0WJ
|
$220.52 Million |
|
APAQ Technology Co Ltd
TW:6449
|
$220.37 Million |
|
YeaShin International Development Co Ltd
TWO:5213
|
$220.36 Million |
|
Shenzhen Bioeasy Biotechnology Co. Ltd.
SHE:300942
|
$220.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hangzhou Minsheng Healthcare Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,473,060,212 to 1,530,846,241, a change of 57,786,029 (3.9%).
- Net income of 91,834,052 contributed positively to equity growth.
- Dividend payments of 35,655,433 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥91.83 Million | +6.0% |
| Dividends Paid | CN¥35.66 Million | -2.33% |
| Other Changes | CN¥1.61 Million | +0.11% |
| Total Change | CN¥- | 3.92% |
Book Value vs Market Value Analysis
This analysis compares Hangzhou Minsheng Healthcare Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.66x to 3.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CN¥1.93 | CN¥14.76 | x |
| 2022-12-31 | CN¥2.22 | CN¥14.76 | x |
| 2023-12-31 | CN¥4.13 | CN¥14.76 | x |
| 2024-12-31 | CN¥4.29 | CN¥14.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hangzhou Minsheng Healthcare Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.00%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.32%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.14x
- Recent ROE (6.00%) is below the historical average (9.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 13.63% | 14.34% | 0.72x | 1.32x | CN¥18.71 Million |
| 2022 | 13.30% | 14.44% | 0.71x | 1.29x | CN¥19.60 Million |
| 2023 | 5.81% | 14.72% | 0.35x | 1.12x | CN¥-61.67 Million |
| 2024 | 6.00% | 14.32% | 0.37x | 1.14x | CN¥-61.25 Million |
Industry Comparison
This section compares Hangzhou Minsheng Healthcare Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $1,443,093,618
- Average return on equity (ROE) among peers: -7.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hangzhou Minsheng Healthcare Co Ltd (301507) | CN¥1.68 Billion | 13.63% | 0.17x | $220.53 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $177.19 Million | 13.55% | 0.63x | $201.14 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $280.61 Million | 7.70% | 0.99x | $310.45 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $638.18 Million | -181.03% | 3.22x | $202.85 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $477.68 Million | 3.28% | 0.64x | $234.89 Million |
| Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) | $361.29 Million | 26.02% | 0.32x | $146.91 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $9.15 Billion | 2.09% | 0.37x | $1.03 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $278.08 Million | 2.72% | 0.13x | $459.10 Million |
| Chongqing Lummy Pharmaceutical (300006) | $107.91 Million | 22.70% | 0.99x | $476.38 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $1.44 Billion | 5.91% | 0.29x | $1.19 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $1.53 Billion | 18.22% | 0.05x | $893.48 Million |